Workflow
Neurodegenerative disorders treatment
icon
Search documents
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease
Globenewswire· 2025-07-29 11:30
Core Insights - Cognition Therapeutics, Inc. presented positive results from the Phase 2 COG1201 SHIMMER study of zervimesine in dementia with Lewy bodies (DLB) at the Alzheimer's Association International Conference 2025 [1][2] - The SHIMMER study demonstrated zervimesine's significant impact on neuropsychiatric symptoms, with DLB patients showing an average of 86% improvement compared to placebo [2][3] - Zervimesine's efficacy in Alzheimer's disease was also highlighted in the Phase 2 SHINE study, where it was found to halt cognitive decline in patients with lower plasma p-tau217 levels by 129% and 91% for mild and moderate cases, respectively [4] Study Details - The SHIMMER study enrolled 130 adults with mild-to-moderate DLB, randomized to receive either zervimesine or placebo for six months [6][7] - The SHINE study included 153 adults with mild-to-moderate Alzheimer's disease, also randomized to receive zervimesine or placebo for six months [9][10] - Both studies met their primary endpoint of safety and tolerability, supported by approximately $30 million in grants from the National Institute on Aging [8][10] Biomarker Findings - Plasma p-tau217 levels were identified as a potential biomarker to predict which Alzheimer's patients would benefit most from zervimesine treatment [1][4] - Significant reductions in plasma glial fibrillary acidic protein (GFAP) were observed in SHINE participants with lower p-tau217 levels, indicating a potential impact on neuroinflammation [5][4] - The studies also showed trends towards normalization of neurofilament light (NfL) and amyloid beta species, suggesting zervimesine's influence on Alzheimer's disease biology [5][4] Company Overview - Cognition Therapeutics, Inc. focuses on developing innovative therapeutics for neurodegenerative disorders, with zervimesine as its lead candidate [13] - Zervimesine is an investigational oral medication aimed at treating Alzheimer's disease and DLB, targeting the toxic effects of protein buildup in the brain [11][13] - The company has received FDA Fast Track designation for zervimesine in Alzheimer's disease, indicating its potential significance in addressing unmet medical needs [11]
Brainstorm Cell Therapeutics(BCLI) - 2025 Q1 - Earnings Call Transcript
2025-05-19 13:30
Financial Data and Key Metrics Changes - The company is focused on executing the clinical development plan for NurOwn and has received FDA clearance to initiate a pivotal Phase 3b trial for ALS [6][10] - Financial constraints have been acknowledged, but the company has made significant strides in trial preparations despite limited resources [13][25] Business Line Data and Key Metrics Changes - The NurOwn technology platform is central to the company's strategy, with ongoing clinical trials aimed at demonstrating its therapeutic benefits [6][12] - The company is actively negotiating clinical trial agreements with approximately 15 leading clinical centers across the U.S. for the Phase 3b trial [10][25] Market Data and Key Metrics Changes - The ALS community's strong interest in NurOwn is highlighted by the engagement of renowned ALS clinicians and researchers [10] - The company participated in the annual ALF Drug Development Summit, indicating its active involvement in the ALS therapeutic development landscape [12] Company Strategy and Development Direction - The company aims to secure strategic funding to support the trial, with a focus on partnerships and non-dilutive grants [14][26] - Expansion of manufacturing capabilities in the U.S. is a key strategic objective, with plans to announce a letter of intent with a U.S.-based facility [30] Management's Comments on Operating Environment and Future Outlook - Management emphasized the urgency for innovative therapeutic options in ALS and the commitment to executing the trial with scientific rigor [11][12] - The company is optimistic about the potential of NurOwn and is preparing for various funding opportunities to ensure timely trial commencement [14][26] Other Important Information - The trial, named "Endurance," is designed to resonate with the ALS community, reflecting the strength and resilience of ALS patients [27] - The company is encouraged by progress in its exosome program, which shows potential in treating respiratory and inflammatory diseases [34] Q&A Session Summary Question: Can you start the trial without proper funding? - Management stated that while significant progress has been made, proper funding is essential to commence the trial [25][26] Question: What is the meaning of the trial name "Endurance"? - The name was chosen to resonate with the ALS community and reflects the company's commitment to delivering a therapeutic option for ALS [27] Question: Will the company also be producing in the U.S.? - The company confirmed plans to expand its manufacturing footprint in the U.S. and will announce a letter of intent with a U.S.-based facility [30] Question: Can you update on any advances in the exosome program? - Management expressed encouragement regarding the exosome program's progress and is preparing to advance it towards clinical development [34] Question: Have you had any communications with FDA regarding stratification by UNC13A? - Management indicated that while the FDA has not approved any biomarker as a surrogate, they are excited about the genetic discoveries and will explore them further [39][40] Question: Can the mechanism of action be used as part of the data package for the next BLA? - Management confirmed that the protective effect observed in cell cultures could support the data package for future filings [43] Question: How many clinical trial sites are you looking to open? - Management confirmed plans to open approximately 15 clinical trial sites and is finalizing agreements to begin patient enrollment [48][50]
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East
GlobeNewswire News Room· 2025-04-21 11:30
Core Insights - Anavex Life Sciences Corp. is focused on developing innovative treatments for Alzheimer's disease and other CNS disorders, with a recent presentation highlighting the clinical efficacy of their drug candidate, Blarcamesine [1][4] Group 1: Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker AVXL, dedicated to developing therapeutics for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders [4] - The company's lead drug candidate, ANAVEX2-73 (Blarcamesine), has completed multiple clinical trials, including Phase 2a and Phase 2b/3 for Alzheimer's disease, and has shown potential in treating Parkinson's disease dementia and Rett syndrome [4] - ANAVEX2-73 is designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, with preclinical studies indicating its ability to halt or reverse Alzheimer's disease progression [4] Group 2: Recent Developments - Marwan Noel Sabbagh, MD, presented findings on Blarcamesine's novel mechanism for Alzheimer's disease at the 9th International Conference on Alzheimer's Disease and Related Disorders held in Abu Dhabi [1][2] - The conference gathered a diverse group of healthcare professionals and researchers from the MENA region, USA, and Europe, focusing on epidemiology and healthcare delivery related to Alzheimer's disease [2]
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025
Newsfilter· 2025-03-25 11:30
Core Insights - Cognition Therapeutics, Inc. is set to present biomarker results from the Phase 2 SHINE study of zervimesine (CT1812) for mild-to-moderate Alzheimer's disease at the AD/PD 2025 Conference in Vienna, Austria from April 1-5, 2025 [1] - The presentation will focus on key proteins, or biomarkers, collected from blood samples, including neurofilament light (NfL) chain, glial fibrillary acidic protein (GFAP), amyloid beta (Aβ), and tau species (p-Tau217 and p-Tau218), which are associated with Alzheimer's disease progression [2] Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system [4] - The company is currently investigating zervimesine (CT1812) in clinical programs for dementia with Lewy bodies and Alzheimer's disease, including the ongoing START study in early Alzheimer's disease [4] - Zervimesine is believed to regulate impaired pathways in these diseases through its interaction with the sigma-2 receptor, which represents a distinct mechanism from other treatment approaches [4] Presentation Details - Dr. Mary Hamby will present findings from the SHINE study, highlighting the impact of zervimesine on disease biology through biomarker changes compared to placebo [3] - The presentation will include several key topics: 1. Positive impact of CT1812 treatment on plasma biomarkers in a lower p-tau217 subgroup [3] 2. CSF proteomic biomarker analysis identifying effects of CT1812 in Alzheimer's disease [3] 3. Identification of CSF proteins correlating with cognitive outcomes in the SHINE study participants [3] 4. Molecular correlates with CT1812 treatment-related decrease in NfL CSF levels [3]
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025
Globenewswire· 2025-03-25 11:30
Core Insights - Cognition Therapeutics, Inc. will present biomarker results from the Phase 2 SHINE study of zervimesine (CT1812) for Alzheimer's disease at the AD/PD 2025 Conference [1] - The study focuses on key proteins, or biomarkers, associated with Alzheimer's disease progression, including neurofilament light (NfL), glial fibrillary acidic protein (GFAP), amyloid beta (Aβ), and tau species [2] - The analysis aims to provide insights into the impact of zervimesine on disease biology by comparing biomarker changes in participants receiving the drug versus those on placebo [3] Presentation Details - The podium presentation titled "Positive Impact of CT1812 Treatment on Plasma Biomarkers in Lower p-tau217 Subgroup Aligns with Clinical Benefits in Mild-to-Moderate AD Patients" is scheduled for April 1, 2025, at 2:45 PM CET [4] - Additional poster presentations will cover CSF proteomic biomarker analysis, identification of CSF proteins correlating with cognitive outcomes, and molecular correlates with treatment-related decreases in NfL CSF levels [4] Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related neurodegenerative disorders [5] - The lead candidate, zervimesine (CT1812), is being investigated in clinical programs for dementia with Lewy bodies and Alzheimer's disease, including the ongoing START study [5] - The company believes zervimesine can regulate impaired pathways in these diseases through its interaction with the sigma-2 receptor, which is distinct from other treatment approaches [5]